Congressman Proposes Biotech, Medicines Should Go on Export Control List
Rep. Ted Yoho, R-Fla., said he will seek to amend the Export Control Reform Act of 2018 to add biotech and medicines to the list of sensitive products that should be subject to analysis on whether their sale to some…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
countries would endanger U.S. national security. Yoho was speaking at a House Foreign Affairs Committee hearing April 17, where the bill passed unanimously out of committee. The last export control legislation expired in 2001, and the administration has continued an export control regime under emergency powers. The bill instructs the administration to maintain a control list, to update it as emerging technologies evolve, and to adjust the level of control of items as conditions change. It also says the maximum fine in a civil case can be twice the value of the exports that were sold to a party that was ineligible to import those items, but if the value was less than $150,000, the maximum fine can be $300,000. In criminal cases, the maximum fine could be $1 million.